RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Low-Dose Aspirin for the Prevention of Preterm Delivery in Nulliparous Women With a Singleton Pregnancy (ASPIRIN)
A Randomized, Double-blind, Placebo-Controlled Trial
Hoffman, M. K., Goudar, S. S., Kodkany, B. S., Metgud, M., Somannavar, M., Okitawutshu, J., Lokangaka, A., Tshefu, A., Bose, C. L., Mwapule, A., Mwenechanya, M., Chomba, E., Carlo, W. A., Chicuy, J., Figueroa, L., Garces, A., Krebs, N. F., Jessani, S., Zehra, F., ... Derman, R. J. (2020). Low-Dose Aspirin for the Prevention of Preterm Delivery in Nulliparous Women With a Singleton Pregnancy (ASPIRIN): A Randomized, Double-blind, Placebo-Controlled Trial. Obstetrical & Gynecological Survey, 75(6), 325-327. https://doi.org/10.1097/ogx.0000000000000814
Preterm birth, or delivery before 37 weeks, is one of the most common causes of infant mortality. New evidence has shown that women who take low-dose aspirin (81 mg) may be at lower risk of preeclampsia.
